Cancer Res Treat.  2013 Dec;45(4):343-348.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

• Lee JY
• Lim SH
• Lee JY
• Kim JH
• Choi KH
• Park K
• Sun JM
• Ahn JS
• Ahn MJ

Abstract

Tumor lysis syndrome (TLS) has rarely been observed in solid tumors. We report on a case of a patient with advanced invasive thymoma who developed tumor lysis syndrome after chemotherapy. The potential complications of TLS should be considered in treatment of extensive thymoma.

Keyword

Thymoma; Drug therapy; Tumor lysis syndrome; Hyperuricemia; Acute kidney injury

MeSH Terms

Acute Kidney Injury
Drug Therapy
Humans
Hyperuricemia
Thymoma*
Tumor Lysis Syndrome*

Figure

• 

  Fig. 1 (A) Chest X-ray, obtained at diagnosis. Huge anterior mediastinal mass extending into the right lung with right pleural effusion. (B) Contrast-enhanced computed tomographic scan, obtained at diagnosis. Extensive soft-tissue mass in the anterior mediastinum extending into the right hemithorax and pericardial involvement.

• 

  Fig. 2 Biopsy specimen of the tumor. The tumor was characterized by a predominant population of thymic epithelial cells and a significantly reduced small lymphocytic population (H&E staining, ×300).

• 

  Fig. 3 (A) Contrast-enhanced computed tomographic scan, obtained at progression showed increased size of thymoma, causing narrowing of the superior vena cava and compression of the carina. (B) Contrast-enhanced computed tomographic scan, obtained after two cycles of paclitaxel and ifosfamide combination chemotherapy showed marked interval improvement of the anterior mediastinal mass with pleural and pericarial seeding.

• 

  Fig. 4 Levels of urate (A), potassium (B), phosphorous (C), calcium (D), lactate dehydrogenase (LDH) (E), and creatinine (F) following chemotherapy. CRRT, continuous renal replacement therapy.

Reference

1. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010; 55(5 Suppl 3):S1–S13. PMID: 20420966.

2. Cairo MS, Coiffier B, Reiter A, Younes A. TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010; 149:578–586. PMID: 20331465.

3. Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005; 2:188–191. PMID: 18628171.

4. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol. 2003; 51:187–192. PMID: 12655435.

5. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006; 18:773–780. PMID: 17168213.

6. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011; 364:1844–1854. PMID: 21561350.

7. Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies: report of a case and review of the literature. Am J Clin Oncol. 1994; 17:502–505. PMID: 7977169.

8. Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999; 85:1055–1059. PMID: 10091788.